SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Omkar Speciality Chemicals forays into pharmaceutical business

10 Apr 2012 Evaluate

Omkar Speciality Chemicals has forayed into pharmaceutical business with its recent acquisition of LASA Laboratory located at Mahad in Raigad district, which has been an established player in the anthelmintic/ veterinary API segment with state-of-the--art API manufacturing facility. This acquisition is strategic for the company in terms of addition of new verticals as well as value addition.

The above acquisition will enable the company to focus on manufacturing anthelmintics, such as Albendazol EP, Albendazole IP/USP, Cyromazine, Fenbendazole, BP VET/ EP, Nitroxynil BP Vet, Ricobendazole, Toldimphos Sodium and Triclabendazole.

The API division is already in operations, and will initially focus on continuing the existing API business of LASA Laboratory, which has massive demand in India and abroad. The products are used as anthelmintics or deworming agents for veterinary. Currently, the product portfolio in this division comprises 10 products in the veterinary anthelmentics segment, mainly Benzimidazoles and other active pharma ingredients.

In addition, Omkar Speciality Chemicals has also plans to manufacture APIs with forward integration of some of the key intermediates which are currently being manufactured in the company.

Omkar Speciality Chemicals is mainly engaged in the manufacture and sale of speciality chemicals viz., selenium compounds, iodine compounds, molybdenum compounds etc. and pharma intermediates viz., Potassium Iodate, Bismuth Ammonium Citrate, Bromoform etc. 

Omkar SpecialityChem Share Price

3.60 0.00 (0.00%)
28-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3865.25
Tata Chemicals 761.95
SRF 2798.45
Pidilite Inds. 1436.40
Deepak Nitrite 1861.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×